Success Metrics

Clinical Success Rate

70.0%

Based on 7 completed trials

Completion Rate

70%(7/10)

Active Trials

0(0%)

Results Posted

29%(2 trials)

Terminated

3(23%)

Phase Distribution

Ph phase_1

38%

Ph phase_4

38%

Ph not_applicable

15%

Ph phase_3

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

5(38.5%)

Phase 3Large-scale testing

1(7.7%)

Phase 4Post-market surveillance

5(38.5%)

N/ANon-phased studies

2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Terminated(3)

Other(3)

Detailed Status

Completed7

unknown3

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

70.0%

Most Advanced

Phase 4

Trials by Phase

Phase 15 (38.5%)

Phase 31 (7.7%)

Phase 45 (38.5%)

N/A2 (15.4%)

Trials by Status

unknown323%

completed754%

terminated323%

Recent Activity

0 active trials

Showing 5 of 13

completedphase_1

Study of TCP-ATRA for Adult Patients With AML and MDS

NCT02273102

unknownphase_1

Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)

NCT02717884

completedphase_4

Clinical Trials (13)

Showing 13 of 13 trials

NCT02273102Phase 1

Study of TCP-ATRA for Adult Patients With AML and MDS

Completed

NCT02717884Phase 1

Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)

Unknown

NCT01430455Phase 4

Tranylcypromine Treatment of Bipolar Depression

Completed

NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated

NCT00223691Phase 1

Treatment of Orthostatic Hypotension in Autonomic Failure

Completed

NCT02261779Phase 1

Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible

Unknown

NCT01031810Phase 4

PET Biomarkers in Treatment Resistant Depression

Terminated

NCT01896349Not Applicable

Interpersonal Psychotherapy for Treatment Resistant Depression

Unknown

NCT00296686Phase 4

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

Terminated

NCT00021528Phase 4

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

Completed

NCT00653393Phase 1

Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions

Completed

NCT00012558Not Applicable

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

Completed

NCT00177567Phase 4

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Completed

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13